Another important question is whether the pre-RC findings reported here in the BRCA2-mutant setting extend to cancers with BRCA1 loss, and whether the genetic background, such as loss of p53, PTEN, and/or RB1, influences the resistance phenotype. The gene discussed is PTEN; the disease is cancer.